Exelixis (EXEL), Bristol-Myers Squibb (BMY) Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the companies have entered into a clinical development ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
